Question 1

My patient is on a benzodiazepine and starting exposure therapy—is that a problem?

Accepted Answer

Yes, benzodiazepines interfere with exposure therapy through two mechanisms: they suppress the arousal needed for expectancy violation (the core of extinction learning), and they create an 'interoceptive context' where the brain learns safety is a drug state, not the environment. Bouton 1990 showed fear extinction under benzodiazepines fails to transfer to drug-free states. Marks 1993 trial found alprazolam + exposure showed initial benefit (RR 1.25) that entirely reversed on discontinuation (RR 0.62). Westra 2002 found PRN benzodiazepine use significantly predicted CBT failure; daily scheduled doses did not differ from unmedicated. The critical distinction: if benzodiazepines are used PRN (as-needed), they interfere by allowing avoidance and reinforcing the 'anxious - medicate' loop. If used as scheduled daily doses not contingent on anxiety, they may be less disruptive. Best practice: taper benzodiazepines before starting exposure, or maintain them at fixed daily doses without PRN use.

Question 2

How does benzodiazepine use interfere with exposure/extinction learning?

Accepted Answer

Yes, benzodiazepines interfere with exposure therapy through two mechanisms: they suppress the arousal needed for expectancy violation (the core of extinction learning), and they create an 'interoceptive context' where the brain learns safety is a drug state, not the environment. Bouton 1990 showed fear extinction under benzodiazepines fails to transfer to drug-free states. Marks 1993 trial found alprazolam + exposure showed initial benefit (RR 1.25) that entirely reversed on discontinuation (RR 0.62). Westra 2002 found PRN benzodiazepine use significantly predicted CBT failure; daily scheduled doses did not differ from unmedicated. The critical distinction: if benzodiazepines are used PRN (as-needed), they interfere by allowing avoidance and reinforcing the 'anxious - medicate' loop. If used as scheduled daily doses not contingent on anxiety, they may be less disruptive. Best practice: taper benzodiazepines before starting exposure, or maintain them at fixed daily doses without PRN use.

Question 3

If I need to bridge with a benzodiazepine, when should I stop it before starting exposure?

Accepted Answer

Yes, benzodiazepines interfere with exposure therapy through two mechanisms: they suppress the arousal needed for expectancy violation (the core of extinction learning), and they create an 'interoceptive context' where the brain learns safety is a drug state, not the environment. Bouton 1990 showed fear extinction under benzodiazepines fails to transfer to drug-free states. Marks 1993 trial found alprazolam + exposure showed initial benefit (RR 1.25) that entirely reversed on discontinuation (RR 0.62). Westra 2002 found PRN benzodiazepine use significantly predicted CBT failure; daily scheduled doses did not differ from unmedicated. The critical distinction: if benzodiazepines are used PRN (as-needed), they interfere by allowing avoidance and reinforcing the 'anxious - medicate' loop. If used as scheduled daily doses not contingent on anxiety, they may be less disruptive. Best practice: taper benzodiazepines before starting exposure, or maintain them at fixed daily doses without PRN use.

Question 4

Can PRN benzodiazepine use during CBT be distinguished from scheduled daily use?

Accepted Answer

Yes, benzodiazepines interfere with exposure therapy through two mechanisms: they suppress the arousal needed for expectancy violation (the core of extinction learning), and they create an 'interoceptive context' where the brain learns safety is a drug state, not the environment. Bouton 1990 showed fear extinction under benzodiazepines fails to transfer to drug-free states. Marks 1993 trial found alprazolam + exposure showed initial benefit (RR 1.25) that entirely reversed on discontinuation (RR 0.62). Westra 2002 found PRN benzodiazepine use significantly predicted CBT failure; daily scheduled doses did not differ from unmedicated. The critical distinction: if benzodiazepines are used PRN (as-needed), they interfere by allowing avoidance and reinforcing the 'anxious - medicate' loop. If used as scheduled daily doses not contingent on anxiety, they may be less disruptive. Best practice: taper benzodiazepines before starting exposure, or maintain them at fixed daily doses without PRN use.

PsychHQ

Benzodiazepines and Exposure Therapy: Why Context Matters for Inhibitory Learning